JEFFREY L JORGENSEN to Humans
This is a "connection" page, showing publications JEFFREY L JORGENSEN has written about Humans.
Connection Strength
0.601
-
Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leuk Res. 2021 12; 111:106704.
Score: 0.016
-
Prognostic Impact of Metastatic Site and Pattern in Patients with Metastatic Head and Neck Cancer. Laryngoscope. 2021 06; 131(6):E1838-E1846.
Score: 0.015
-
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117.
Score: 0.011
-
B-acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol. 2015 Sep; 144(3):393-410.
Score: 0.011
-
Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014 Dec; 142(6):837-44.
Score: 0.010
-
Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow. Arch Pathol Lab Med. 2014 Sep; 138(9):1210-4.
Score: 0.010
-
Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time? J Natl Compr Canc Netw. 2012 Aug; 10(8):1029-36.
Score: 0.009
-
Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy. Am J Clin Pathol. 2012 Apr; 137(4):634-40.
Score: 0.008
-
Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S49-53.
Score: 0.008
-
Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. Am J Clin Pathol. 2011 Mar; 135(3):365-73.
Score: 0.008
-
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8.
Score: 0.007
-
Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol. 2009 Nov; 132(5):692-8.
Score: 0.007
-
Flow cytometric immunophenotyping of anaplastic large cell lymphoma. Arch Pathol Lab Med. 2009 Jan; 133(1):49-56.
Score: 0.007
-
Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. Cytometry B Clin Cytom. 2008 Nov; 74(6):341-8.
Score: 0.007
-
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2.
Score: 0.007
-
State of the Art Symposium: flow cytometry in the diagnosis of lymphoproliferative disorders by fine-needle aspiration. Cancer. 2005 Dec 25; 105(6):443-51.
Score: 0.005
-
Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005 Jun; 18(6):806-15.
Score: 0.005
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
Score: 0.005
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.005
-
Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453.
Score: 0.004
-
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44.
Score: 0.004
-
Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma. Haematologica. 2023 03 01; 108(3):895-899.
Score: 0.004
-
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
Score: 0.004
-
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022 12 13; 12(12):165.
Score: 0.004
-
Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors. Cytometry B Clin Cytom. 2022 11; 102(6):440-447.
Score: 0.004
-
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411.
Score: 0.004
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.004
-
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141.
Score: 0.004
-
Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom. 2022 07; 102(4):283-291.
Score: 0.004
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.004
-
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021 12 30; 138(26):2753-2767.
Score: 0.004
-
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single-institution experience. Cytometry B Clin Cytom. 2022 03; 102(2):123-133.
Score: 0.004
-
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.
Score: 0.004
-
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
Score: 0.004
-
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021 12; 62(13):3296-3299.
Score: 0.004
-
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
Score: 0.004
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.004
-
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
Score: 0.004
-
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 04 01; 106(4):1047-1055.
Score: 0.004
-
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
Score: 0.004
-
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
Score: 0.004
-
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
Score: 0.004
-
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020 12 22; 4(24):6117-6126.
Score: 0.004
-
CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):e317-e320.
Score: 0.004
-
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/S?zary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom. 2021 03; 100(2):183-191.
Score: 0.004
-
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
Score: 0.004
-
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
Score: 0.004
-
Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck. Clin Transl Oncol. 2020 Nov; 22(11):2009-2016.
Score: 0.004
-
CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Hum Pathol. 2020 04; 98:1-9.
Score: 0.004
-
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959.
Score: 0.004
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.004
-
Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom. 2020 01; 98(1):36-42.
Score: 0.003
-
Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
Score: 0.003
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.003
-
Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma. 2019 11; 60(11):2829-2831.
Score: 0.003
-
Mandibular Invasion by Oral Squamous Cell Carcinoma: Clinicopathologic Features of 74 Cases. Otolaryngol Head Neck Surg. 2019 06; 160(6):1034-1041.
Score: 0.003
-
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.
Score: 0.003
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
Score: 0.003
-
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 02; 94(2):257-265.
Score: 0.003
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.003
-
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755.
Score: 0.003
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.003
-
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311.
Score: 0.003
-
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
Score: 0.003
-
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.
Score: 0.003
-
Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. Ann Hematol. 2018 Oct; 97(10):1775-1783.
Score: 0.003
-
Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
Score: 0.003
-
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
Score: 0.003
-
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
Score: 0.003
-
Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
Score: 0.003
-
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.
Score: 0.003
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.003
-
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018 03 22; 131(12):1275-1291.
Score: 0.003
-
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018 02; 31(2):327-336.
Score: 0.003
-
How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? Clin Lab Med. 2017 12; 37(4):787-802.
Score: 0.003
-
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018 01; 32(1):241-244.
Score: 0.003
-
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517.
Score: 0.003
-
A common complication of myelofibrosis presenting as a rare finding in cerebrospinal fluid cytology. Diagn Cytopathol. 2017 Nov; 45(11):1039-1041.
Score: 0.003
-
Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw. 2017 06; 15(6):790-796.
Score: 0.003
-
CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience. Am J Clin Pathol. 2017 04 01; 147(4):357-363.
Score: 0.003
-
Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. Histopathology. 2017 Apr; 70(5):821-831.
Score: 0.003
-
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285.
Score: 0.003
-
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. Clin Cancer Res. 2017 07 01; 23(13):3385-3395.
Score: 0.003
-
Distinguishing Between Hepatosplenic T-cell Lymphoma and ?d T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol. 2017 01; 41(1):82-93.
Score: 0.003
-
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581.
Score: 0.003
-
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
Score: 0.003
-
Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017 Jan; 52(1):20-27.
Score: 0.003
-
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
Score: 0.003
-
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. 2017 Jan; 52(1):28-33.
Score: 0.003
-
Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma. J Natl Compr Canc Netw. 2016 08; 14(8):939-44.
Score: 0.003
-
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
Score: 0.003
-
Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget. 2016 Jun 21; 7(25):38122-38132.
Score: 0.003
-
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6.
Score: 0.003
-
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Am J Clin Pathol. 2016 Jun; 145(6):769-77.
Score: 0.003
-
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
Score: 0.003
-
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.
Score: 0.003
-
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
Score: 0.003
-
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 07; 30(7):1606-9.
Score: 0.003
-
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9.
Score: 0.003
-
CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leuk Lymphoma. 2016 08; 57(8):1965-8.
Score: 0.003
-
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr; 30(4):929-36.
Score: 0.003
-
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol. 2016 Apr; 50:109-17.
Score: 0.003
-
De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol. 2015; 32(8):535-47.
Score: 0.003
-
Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC. J Hematol Oncol. 2015 Oct 29; 8:121.
Score: 0.003
-
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
Score: 0.003
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
Score: 0.003
-
Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
Score: 0.003
-
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016 Jan; 90(1):26-30.
Score: 0.003
-
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2.
Score: 0.003
-
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76.
Score: 0.003
-
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015 Nov; 29(11):2263-6.
Score: 0.003
-
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015 Jun; 90(6):504-10.
Score: 0.003
-
General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
Score: 0.003
-
Adhesive capsulitis mimicking metastasis on 18F-FDG-PET/CT. Clin Nucl Med. 2015 Feb; 40(2):e145-7.
Score: 0.003
-
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19; 125(12):1883-9.
Score: 0.003
-
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015 Apr; 87(4):346-56.
Score: 0.003
-
The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1903-5.
Score: 0.003
-
Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. Cytometry B Clin Cytom. 2015 Jul-Aug; 88(4):236-43.
Score: 0.003
-
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and S?zary syndrome. Clin Cancer Res. 2015 Jan 15; 21(2):274-85.
Score: 0.002
-
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9.
Score: 0.002
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
Score: 0.002
-
Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Arch Pathol Lab Med. 2014 Jul; 138(7):903-9.
Score: 0.002
-
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60.
Score: 0.002
-
Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014 Sep; 49(9):1129-38.
Score: 0.002
-
Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93.
Score: 0.002
-
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32.
Score: 0.002
-
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.
Score: 0.002
-
Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e115-8.
Score: 0.002
-
Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. Leuk Lymphoma. 2014 Sep; 55(9):2215-6.
Score: 0.002
-
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26.
Score: 0.002
-
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80.
Score: 0.002
-
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.
Score: 0.002
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
Score: 0.002
-
Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012 Nov; 138(5):744-50.
Score: 0.002
-
Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012 Jul; 36(7):1000-8.
Score: 0.002
-
Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. J Clin Pathol. 2012 Sep; 65(9):823-9.
Score: 0.002
-
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
Score: 0.002
-
Multi-color CD34? progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res. 2012 Aug; 36(8):974-81.
Score: 0.002
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
Score: 0.002
-
CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol. 2012 Feb; 137(2):213-9.
Score: 0.002
-
A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol. 2013 Sep; 52(9):1111-4.
Score: 0.002
-
Molecular components of T-cell recognition. Annu Rev Immunol. 1992; 10:835-73.
Score: 0.002
-
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 06; 118(14):3818-23.
Score: 0.002
-
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95.
Score: 0.002
-
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011 Sep 01; 117(17):4009-17.
Score: 0.002
-
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood. 2011 Apr 14; 117(15):4076-84.
Score: 0.002
-
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
Score: 0.002
-
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7.
Score: 0.002
-
Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. Arch Pathol Lab Med. 2010 May; 134(5):759-65.
Score: 0.002
-
Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis. Am J Clin Pathol. 2010 Feb; 133(2):314-20.
Score: 0.002
-
TCR-Vbeta flow cytometric analysis of peripheral blood for assessing clonality and disease burden in patients with T cell large granular lymphocyte leukaemia. J Clin Pathol. 2010 Feb; 63(2):141-6.
Score: 0.002
-
Flow cytometric detection of peripheral blood involvement by mycosis fungoides and S?zary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol. 2010 Feb; 23(2):284-95.
Score: 0.002
-
Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Hum Pathol. 2010 Jan; 41(1):79-87.
Score: 0.002
-
Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. Leuk Res. 2009 Nov; 33(11):e186-8.
Score: 0.002
-
A human T cell-specific molecule is a member of a new gene family. 1988. J Immunol. 2009 Apr 01; 182(7):3947-54.
Score: 0.002
-
T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. Am J Clin Pathol. 2009 Mar; 131(3):347-56.
Score: 0.002
-
Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica. 2009 Jan; 94(1):29-37.
Score: 0.002
-
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009 Jan; 22(1):50-7.
Score: 0.002
-
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7.
Score: 0.002
-
Bone marrow involvement by marginal zone B-cell lymphomas of different types. Am J Clin Pathol. 2008 May; 129(5):714-22.
Score: 0.002
-
Immunophenotypic study of basophils by multiparameter flow cytometry. Arch Pathol Lab Med. 2008 May; 132(5):813-9.
Score: 0.002
-
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008 Apr; 141(1):36-40.
Score: 0.002
-
Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Tissue Antigens. 2007 Aug; 70(2):105-9.
Score: 0.002
-
Unusual expression of CD94 on CD8+ TCR-alpha beta T cells in infectious mononucleosis. Ann Diagn Pathol. 2007 Feb; 11(1):55-60.
Score: 0.001
-
Follicular lymphoma in staging bone marrow specimens: correlation of histologic findings with the results of flow cytometry immunophenotypic analysis. Arch Pathol Lab Med. 2007 Feb; 131(2):282-7.
Score: 0.001
-
Radiolucent lines at the proximal end of the LEG simulating fractures. Rontgenblatter. 1986 Sep; 39(9):258-9.
Score: 0.001
-
Rosai-Dorfman disease misdiagnosed as active tuberculosis. Leuk Lymphoma. 2006 Jul; 47(7):1441-2.
Score: 0.001
-
A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia. 2006 Sep; 20(9):1638-40.
Score: 0.001
-
Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62.
Score: 0.001
-
Restricted kappa/lambda light chain ratio by flow cytometry in germinal center B cells in Hashimoto thyroiditis. Am J Clin Pathol. 2006 Jan; 125(1):42-8.
Score: 0.001
-
Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia. Am J Clin Pathol. 2005 Sep; 124(3):414-20.
Score: 0.001
-
Role of radiation therapy in a patient with primary pancreatic lymphoma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):143-5.
Score: 0.001
-
Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. Virology. 2005 Nov 10; 342(1):38-46.
Score: 0.001
-
Differential ability of two simian virus 40 strains to induce malignancies in weanling hamsters. Virology. 2004 Dec 05; 330(1):168-77.
Score: 0.001
-
Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol. 2004 Nov 16; 44(10):2091-3.
Score: 0.001
-
The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore). 2003 Mar; 82(2):77-81.
Score: 0.001
-
Composite thymoma and chronic lymphocytic leukemia/small lymphocytic lymphoma involving the anterior mediastinum. Arch Pathol Lab Med. 2003 Feb; 127(2):E76-9.
Score: 0.001
-
Association between SV40 and non-Hodgkin's lymphoma. Leuk Lymphoma. 2003; 44 Suppl 3:S33-9.
Score: 0.001
-
Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2002 Jun 01; 99(11):4250-1.
Score: 0.001
-
Association between simian virus 40 and non-Hodgkin lymphoma. Lancet. 2002 Mar 09; 359(9309):817-23.
Score: 0.001
-
AIDS-related systemic non-Hodgkin's lymphoma at a large community program. AIDS Res Hum Retroviruses. 2002 Mar 01; 18(4):237-42.
Score: 0.001
-
Thermophilic multidrug-resistant Campylobacter fetus infection with hypersplenism and histiocytic phagocytosis in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2001 Jan 15; 32(2):295-6.
Score: 0.001
-
Unilocular retroperitoneal cyst of mesothelial origin presenting as a renal mass. Arch Pathol Lab Med. 2000 May; 124(5):766-9.
Score: 0.001
-
Leiomyosarcomas of the oral cavity: an unusual topographic subset easily mistaken for nonmesenchymal tumours. Histopathology. 2000 Mar; 36(3):210-20.
Score: 0.001
-
Characteristic proliferations of reticular and dendritic cells in angioimmunoblastic lymphoma. Am J Surg Pathol. 1998 Aug; 22(8):956-64.
Score: 0.001
-
Transfer of putative complementarity-determining region loops of T cell receptor V domains confers toxin reactivity but not peptide/MHC specificity. J Immunol. 1993 Mar 15; 150(6):2281-94.
Score: 0.001
-
A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988 Aug 01; 141(3):1018-25.
Score: 0.000
-
Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol. 1987 Feb; 104(2):263-75.
Score: 0.000